Corona Remedies IPO Subscription Day 1

Here, the Corona Remedies IPO launched on 8th December 2025. Bidding for the issue will close today, 10th December 2025. The primary aim of the Corona Remedies IPO is to raise ₹655.37 crores from the market. Also, the Corona Remedies IPO has received an impressive level of subscription, indicating that the shares will be listed at an impeccable premium. Scroll down to check the Corona Remedies IPO subscription and details. 

Corona Remedies IPO Details 

The price band for Riddhi Display Equipment’s IPO has been set at ₹1,008 to ₹1,062 per share, and a total of 14 shares are being issued. Let’s segregate the share quota fixed for different categories of investors. 

Corona Remedies IPO Subscription Status

As of now, the Corona Remedies IPO has been subscribed to 0.67 times. Of these, 0.95 times are subscribed by retail investors, 0.84 times by non-institutional investors, and 1.07 times by OIB (Qualified-Institutional Buyers).  

The healthy subscription status indicates that investors are expecting higher returns at the time of Riddhi Display Equipment’s IPO listing on 15th December 2025. Corona Remedies also has a positive outlook behind the fresh issue of shares, which will raise around Rs 655.37  crores.

Corona Remedies IPO GMP Today

We know that higher subscription levels drive grey-market premiums for IPOs. Let’s explore the Corona Remedies IPO GMP for 8th December 2025. 

The grey market premium for this IPO has surged to 0.00% or Rs 138.00 per share. It indicates that the estimated listing price per share is Rs 138.00. Numerous factors played a pivotal role in this jump in the GMP of Corona Remedies IPO. These include higher subscription rates, favourable market sentiment, and investors’ positive attitude towards IPOs. 

About Corona Remedies Ltd.

Corona Remedies was established in August 2004. Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. As of June 30, 2025, the company’s diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory). The company has a pan-India marketing and distribution network with 2,671 medical representatives across 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM, and ensuring deep penetration across therapeutic areas.

Corona Remedies Limited Financials

The company’s financial analysis is essential before applying for the Corona Remedies IPO. Look at the table to learn about Corona Remedies Limited’s financials. 

Explanation

Corona Remedies Limited’s revenue soared by 18% from ₹1,020.93 crores in March 2024  to ₹1,202.35 crores in March 2025. Moreover, the company’s PAT increased by 65% from ₹90.50 crores in March 2024 to ₹149.43 crores in March 2025.

Technical Indicators

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Corona Remedies IPO.

Corona Remedies IPO Listing Expectations

Corona Remedies IPO Highlights: IPO allotment is still pending, as the bid will close today. However, given the current GMP or market sentiment, it is reasonable to expect higher listing gains for the share. A jump of 1.00% in Yash Highlight GMP suggests the estimated listing price per share will be around Rs 138.00.

It will provide higher listing gains to investors who applied for this IPO. Also, the financial fundamentals of this business made it the experts’ top long-term recommendation. 

Corona Remedies IPO Dates

Note: IPO GMP is volatile and depends on market sentiment. Hence, one should conduct their research before investing in it.

Recent Articles

Icodex Publishing Solutions IPO GMP: Day 1 IPO Live Updates

Bluestone Jewellery IPO GMP: Day 1 IPO Live Updates

Highway Infrastructure IPO Listing Preview: What to Expect Now in 2025?

Concord Biotech Q1 Results FY26: Q1 PAT Falls 26.07% to ₹44.06 Crore; Revenue Down 5.47% YoY

Action Construction Equipment Q1 Results FY26: Q1 PAT Rises 16.08% to ₹97.72 Crore; Revenue Down 11.19% YoY

Sawaliya Foods Products IPO Allotment Status Check Online: GMP, Subscription, Price, and More

Corona Remedies IPO Allotment Status Check Online: GMP, Subscription, Price, and More

Mahendra Realtors IPO GMP & Review: Apply or Avoid?

Regaal Resources IPO GMP & Review: Apply or Avoid?

Icodex Publishing Solutions IPO GMP & Review: Apply or Avoid?